{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:48:46Z","timestamp":1788536926129,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s12032-018-1120-9","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T11:21:50Z","timestamp":1522754510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1585-6410","authenticated-orcid":false,"given":"Joanna","family":"Rupa-Matysek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lembicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza Katarzyna","family":"Rogowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieczys\u0142aw","family":"Komarnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halina","family":"Batura-Gabryel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"issue":"1","key":"1120_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. Cancer J Clin. 2018;68(1):7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21442\n                    \n                  .","journal-title":"Cancer J Clin."},{"issue":"3","key":"1120_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.lungcan.2012.09.007","volume":"78","author":"GC Connolly","year":"2012","unstructured":"Connolly GC, Dalal M, Lin J, Khorana AA. Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer. 2012;78(3):253\u20138. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2012.09.007\n                    \n                  .","journal-title":"Lung Cancer"},{"issue":"1","key":"1120_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lungcan.2014.07.017","volume":"86","author":"WW Mellema","year":"2014","unstructured":"Mellema WW, van der Hoek D, Postmus PE, Smit EF. Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy. Lung Cancer. 2014;86(1):73\u20137. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2014.07.017\n                    \n                  .","journal-title":"Lung Cancer"},{"issue":"6","key":"1120_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1517\/14740330802374262","volume":"7","author":"CA Dasanu","year":"2008","unstructured":"Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf. 2008;7(6):703\u201316. \n                    https:\/\/doi.org\/10.1517\/14740330802374262\n                    \n                  .","journal-title":"Expert Opin Drug Saf."},{"issue":"6","key":"1120_CR5","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","volume":"33","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654\u20136. \n                    https:\/\/doi.org\/10.1200\/jco.2014.59.7351\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"1120_CR6","doi-asserted-by":"publisher","first-page":"vi85","DOI":"10.1093\/annonc\/mdr392","volume":"22","author":"M Mandala","year":"2011","unstructured":"Mandala M, Falanga A, Roila F, Group EGW. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2011;22(Suppl 6):vi85\u201392. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdr392\n                    \n                  .","journal-title":"Ann Oncol."},{"issue":"10","key":"1120_CR7","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","volume":"17","author":"D Farge","year":"2016","unstructured":"Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452\u201366. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(16)30369-2\n                    \n                  .","journal-title":"Lancet Oncol."},{"key":"1120_CR8","unstructured":"Network. NCC. National Comprehensive Cancer Network (Version 1. 2017). \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/meloid_growth.pdf\n                    \n                  . Accessed 10 Feb 2018."},{"issue":"10","key":"1120_CR9","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902\u20137. \n                    https:\/\/doi.org\/10.1182\/blood-2007-10-116327\n                    \n                  .","journal-title":"Blood"},{"issue":"3","key":"1120_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","volume":"7","author":"M Verso","year":"2012","unstructured":"Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291\u20132. \n                    https:\/\/doi.org\/10.1007\/s11739-012-0784-y\n                    \n                  .","journal-title":"Intern Emerg Med"},{"issue":"41","key":"1120_CR11","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1055\/s-0033-1349608","volume":"138","author":"U Pelzer","year":"2013","unstructured":"Pelzer U, Sinn M, Stieler J, Riess H. Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? Dtsch Med Wochenschr. 2013;138(41):2084\u20138. \n                    https:\/\/doi.org\/10.1055\/s-0033-1349608\n                    \n                  .","journal-title":"Dtsch Med Wochenschr"},{"issue":"10","key":"1120_CR12","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","volume":"22","author":"GT Gerotziafas","year":"2017","unstructured":"Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study. Oncologist. 2017;22(10):1222\u201331. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2016-0414\n                    \n                  .","journal-title":"Oncologist"},{"issue":"9","key":"1120_CR13","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","volume":"102","author":"N Es van","year":"2017","unstructured":"van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mahe I, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102(9):1494\u2013501. \n                    https:\/\/doi.org\/10.3324\/haematol.2017.169060\n                    \n                  .","journal-title":"Haematologica"},{"issue":"9","key":"1120_CR14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/jth.13378","volume":"14","author":"AS Mansfield","year":"2016","unstructured":"Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost. 2016;14(9):1773\u20138. \n                    https:\/\/doi.org\/10.1111\/jth.13378\n                    \n                  .","journal-title":"J Thromb Haemost"},{"issue":"8","key":"1120_CR15","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","volume":"2","author":"P Goldstraw","year":"2007","unstructured":"Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706\u201314. \n                    https:\/\/doi.org\/10.1097\/JTO.0b013e31812f3c1a\n                    \n                  .","journal-title":"J Thorac Oncol."},{"issue":"5","key":"1120_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis."},{"issue":"10","key":"1120_CR17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/sj.bjc.6602836","volume":"93","author":"B Colinet","year":"2005","unstructured":"Colinet B, Jacot W, Bertrand D, Lacombe S, Bozonnat MC, Daures JP, et al. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson\u2019s index. Br J Cancer. 2005;93(10):1098\u2013105. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6602836\n                    \n                  .","journal-title":"Br J Cancer"},{"issue":"23","key":"1120_CR18","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1161\/CIR.0000000000000041","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the heart rhythm society. Circulation. 2014;130(23):e199\u2013267. \n                    https:\/\/doi.org\/10.1161\/cir.0000000000000041\n                    \n                  .","journal-title":"Circulation"},{"issue":"1","key":"1120_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.rec.2016.11.033","volume":"70","author":"P Kirchhof","year":"2017","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration With EACTS. Rev Esp Cardiol (Engl Ed). 2017;70(1):50. \n                    https:\/\/doi.org\/10.1016\/j.rec.2016.11.033\n                    \n                  .","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"issue":"8","key":"1120_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/JTO.0b013e31811ea275","volume":"2","author":"V Tagalakis","year":"2007","unstructured":"Tagalakis V, Levi D, Agulnik JS, Cohen V, Kasymjanova G, Small D. High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients. J Thorac Oncol. 2007;2(8):729\u201334. \n                    https:\/\/doi.org\/10.1097\/JTO.0b013e31811ea275\n                    \n                  .","journal-title":"J Thorac Oncol."},{"issue":"3","key":"1120_CR21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.lungcan.2014.10.003","volume":"86","author":"TV Kourelis","year":"2014","unstructured":"Kourelis TV, Wysokinska EM, Wang Y, Yang P, Mansfield AS, Tafur AJ. Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer. Lung Cancer. 2014;86(3):358\u201362. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2014.10.003\n                    \n                  .","journal-title":"Lung Cancer"},{"issue":"4","key":"1120_CR22","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458\u201364. \n                    https:\/\/doi.org\/10.1001\/archinte.166.4.458\n                    \n                  .","journal-title":"Arch Intern Med"},{"key":"1120_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CEOR.S39964","volume":"5","author":"AA Khorana","year":"2013","unstructured":"Khorana AA, Dalal MR, Lin J, Connolly GC. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. ClinicoEcononmics Outcomes Res. 2013;5:101\u20138. \n                    https:\/\/doi.org\/10.2147\/ceor.S39964\n                    \n                  .","journal-title":"ClinicoEcononmics Outcomes Res."},{"issue":"3","key":"1120_CR24","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632\u20134. \n                    https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02374.x\n                    \n                  .","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1120_CR25","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","volume":"34","author":"F Macbeth","year":"2016","unstructured":"Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. J Clin Oncol. 2016;34(5):488\u201394. \n                    https:\/\/doi.org\/10.1200\/jco.2015.64.0268\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"1120_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx716","author":"L Ek","year":"2017","unstructured":"Ek L, Gezelius E, Bergman B, Bendahl PO, Anderson H, Sundberg J, et al. Randomized phase III trial of low molecular weight heparin enoxaparin in addition to standard treatment in small cell lung cancer: the RASTEN trial. Ann Oncol. 2017. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx716\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"1120_CR27","doi-asserted-by":"publisher","first-page":"Cd008500","DOI":"10.1002\/14651858.cd008500.pub4","volume":"12","author":"M Nisio Di","year":"2016","unstructured":"Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016;12:Cd008500. \n                    https:\/\/doi.org\/10.1002\/14651858.cd008500.pub4\n                    \n                  .","journal-title":"Cochrane Database Syst Rev"},{"key":"1120_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","volume":"150","author":"N Es van","year":"2017","unstructured":"van Es N, Franke VF, Middeldorp S, Wilmink JW, Buller HR. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res. 2017;150:30\u20132. \n                    https:\/\/doi.org\/10.1016\/j.thromres.2016.12.013\n                    \n                  .","journal-title":"Thromb Res"},{"issue":"7","key":"1120_CR29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1108898","volume":"366","author":"G Agnelli","year":"2012","unstructured":"Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601\u20139. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1108898\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"3","key":"1120_CR30","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/cncr.27772","volume":"119","author":"AA Khorana","year":"2013","unstructured":"Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648\u201355. \n                    https:\/\/doi.org\/10.1002\/cncr.27772\n                    \n                  .","journal-title":"Cancer"},{"issue":"5","key":"1120_CR31","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/cncr.20893","volume":"103","author":"G Numico","year":"2005","unstructured":"Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005;103(5):994\u20139. \n                    https:\/\/doi.org\/10.1002\/cncr.20893\n                    \n                  .","journal-title":"Cancer"},{"key":"1120_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1479-5876-9-179","volume":"9","author":"S Barni","year":"2011","unstructured":"Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandala M, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9:179. \n                    https:\/\/doi.org\/10.1186\/1479-5876-9-179\n                    \n                  .","journal-title":"J Transl Med."},{"issue":"12","key":"1120_CR33","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.21037\/jtd.2017.11.116","volume":"9","author":"Q Shen","year":"2017","unstructured":"Shen Q, Dong X, Tang X, Zhou J. Risk factors and prognosis value of venous thromboembolism in patients with advanced non-small cell lung cancer: a case-control study. J Thorac Dis. 2017;9(12):5068\u201374. \n                    https:\/\/doi.org\/10.21037\/jtd.2017.11.116\n                    \n                  .","journal-title":"J Thorac Dis."},{"key":"1120_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.thromres.2016.01.002","volume":"139","author":"AA Ashrani","year":"2016","unstructured":"Ashrani AA, Gullerud RE, Petterson TM, Marks RS, Bailey KR, Heit JA. Risk factors for incident venous thromboembolism in active cancer patients: a population based case-control study. Thromb Res. 2016;139:29\u201337. \n                    https:\/\/doi.org\/10.1016\/j.thromres.2016.01.002\n                    \n                  .","journal-title":"Thromb Res"},{"issue":"2","key":"1120_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/j.ajkd.2016.10.039","volume":"70","author":"KL Cheung","year":"2017","unstructured":"Cheung KL, Zakai NA, Folsom AR, Kurella Tamura M, Peralta CA, Judd SE, et al. Measures of kidney disease and the risk of venous thromboembolism in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis. 2017;70(2):182\u201390. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2016.10.039\n                    \n                  .","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1120_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.thromres.2014.04.002","volume":"134","author":"O Konigsbrugge","year":"2014","unstructured":"Konigsbrugge O, Lotsch F, Zielinski C, Pabinger I, Ay C. Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. Thromb Res. 2014;134(1):44\u20139. \n                    https:\/\/doi.org\/10.1016\/j.thromres.2014.04.002\n                    \n                  .","journal-title":"Thromb Res"},{"issue":"11","key":"1120_CR37","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1111\/jth.12411","volume":"11","author":"J Kooiman","year":"2013","unstructured":"Kooiman J, den Exter PL, Cannegieter SC, le Cessie S, del Toro J, Sahuquillo JC, et al. Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment. J Thromb Haemost. 2013;11(11):1968\u201376. \n                    https:\/\/doi.org\/10.1111\/jth.12411\n                    \n                  .","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1120_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/jth.12762","volume":"13","author":"KF Enga","year":"2015","unstructured":"Enga KF, Rye-Holmboe I, Hald EM, Lochen ML, Mathiesen EB, Njolstad I, et al. Atrial fibrillation and future risk of venous thromboembolism: the Tromso study. J Thromb Haemost. 2015;13(1):10\u20136. \n                    https:\/\/doi.org\/10.1111\/jth.12762\n                    \n                  .","journal-title":"J Thromb Haemost"},{"issue":"6","key":"1120_CR39","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/cam4.1054","volume":"6","author":"AG Ording","year":"2017","unstructured":"Ording AG, Horvath-Puho E, Adelborg K, Pedersen L, Prandoni P, Sorensen HT. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med. 2017;6(6):1165\u201372. \n                    https:\/\/doi.org\/10.1002\/cam4.1054\n                    \n                  .","journal-title":"Cancer Med"},{"key":"1120_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217726158","author":"ER Pritchard","year":"2017","unstructured":"Pritchard ER, Murillo JR Jr, Putney D, Hobaugh EC. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. J Oncol Pharm Pract. 2017. \n                    https:\/\/doi.org\/10.1177\/1078155217726158\n                    \n                  .","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"1120_CR41","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s11239-012-0741-7","volume":"34","author":"H Huang","year":"2012","unstructured":"Huang H, Korn JR, Mallick R, Friedman M, Nichols C, Menzin J. Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study. J Thromb Thrombolysis. 2012;34(4):446\u201356. \n                    https:\/\/doi.org\/10.1007\/s11239-012-0741-7\n                    \n                  .","journal-title":"J Thromb Thrombolysis"},{"issue":"17","key":"1120_CR42","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","volume":"31","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189\u2013204. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.49.1118\n                    \n                  .","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1120-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T23:49:51Z","timestamp":1554335391000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1120-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1120-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"8 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"63"}}